PI3K/AKT signaling pathway and leukemia

doi:10.3760/cma.j.issn.1007-1245.2021.06.002

International Medicine and Health Guidance News ›› 2021, Vol. 27 ›› Issue (6): 795-798.DOI: 10.3760/cma.j.issn.1007-1245.2021.06.002

• Scientific Research • Previous Articles Next Articles

PI3K/AKT signaling pathway and leukemia

Wu Jianmin, Jia Xiuhong, Zhang Jian

Department of Pediatrics, Binzhou Medical University Hospital, Binzhou 256603, China

Received:2020-06-04 Online:2021-03-15 Published:2021-04-15
Contact: Jia Xiuhong, Email: jiaxiuhong001@163.com
Supported by:
Natural Science Foundation of Shandong Province (ZR2014HL032); Medical and Health Technology Development Program of Shandong Province (2014WS0183; 2017WSB30031)

PI3K/AKT信号通路与白血病

吴建敏, 贾秀红, 张健

滨州医学院附属医院儿科 256603

通讯作者: 贾秀红,Email:jiaxiuhong001@163.com
基金资助:
山东省自然科学基金项目(ZR2014HL032); 山东省医药卫生科技发展计划项目(2014WS0183; 2017WSB30031)

Abstract

Abstract: Leukemia is a malignant proliferative disease of hematopoietic stem cells derived from bone marrow. The PI3K/AKT signaling pathway is an intracellular signaling pathway, which is closely related to the survival of tumor cells. This paper reviews the correlation between PI3K/AKT signaling pathway and leukemia.

Key words: PI3K/AKT signaling pathway, Leukemia, Inhibitors

摘要： 白血病(leukemia)是一种源于骨髓的造血干细胞恶性增殖性疾病。PI3K/AKT信号通路是一种胞内传导的信号通路,与肿瘤细胞生存息息相关。本文就PI3K/AKT信号通路与白血病的相关性进行综述。

关键词: PI3K/AKT信号通路, 白血病, 抑制剂

Wu Jianmin, Jia Xiuhong, Zhang Jian. PI3K/AKT signaling pathway and leukemia[J]. International Medicine and Health Guidance News, 2021, 27(6): 795-798.

吴建敏, 贾秀红, 张健. PI3K/AKT信号通路与白血病[J]. 国际医药卫生导报, 2021, 27(6): 795-798.

References

[1] Manning BD, Toker A.AKT/PKB Signaling: Navigating the Network[J]. Cell, 2017, 169(3): 381-405. DOI: 10.1016/j.cell.2017.04.001.
[2] Brown JS, Banerji U.Maximising the potential of AKT inhibitors as anti-cancer treatments[J]. Pharmacol Ther, 2017, 172: 101-115. DOI: 10.1016/j.pharmthera.2016.12.001.
[3] Murugan AK, Liu R, Xing M.Identification and characterization of two novel oncogenic mTOR mutations[J]. Oncogene, 2019, 38(26): 5211-5226. DOI: 10.1038/s41388-019-0787-5.
[4] Corti F, Nichetti F, Raimondi A, et al.Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives[J]. Cancer Treat Rev, 2019, 72: 45-55. DOI: 10.1016/j.ctrv.2018.11.001.
[5] Kim D, Dan HC, Park S, et al.AKT/PKB signaling mechanisms in cancer and chemoresistance[J]. Front Biosci, 2005, 10: 975-987. DOI: 10.2741/1592.
[6] Martini M, De Santis MC, Braccini L, et al.PI3K/AKT signaling pathway and cancer: an updated review[J]. Ann Med, 2014, 46(6): 372-383. DOI: 10.3109/07853890.2014.912836.
[7] Fruman DA, Chiu H, Hopkins BD, et al.The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635. DOI: 10.1016/j.cell.2017.07.029
[8] Fruman DA.Regulatory subunits of class IA PI3K[J]. Curr Top Microbiol Immunol, 2010, 346: 225-244. DOI: 10.1007/82_2010_39.
[9] Shiwarski DJ, Darr M, Telmer CA, et al.PI3K class Ⅱαregulatesδ-opioid receptor export from the trans-Golgi network[J]. Mol Biol Cell, 2017, 28(16): 2202-2219. DOI: 10.1091/mbc.e17-01-0030.
[10] Tian L, Zhao Z, Xie L, et al.Mi R-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1via the PI3K/Akt/m TOR pathway[J]. Oncotarget, 2017, 9(4): 4886-4896. DOI: 10.18632/oncotarget.23513.
[11] Mayer IA, Arteaga CL.The PI3K/AKT pathway as a target for cancer treatment[J]. Annu Rev Med, 2016, 67: 11-28. DOI: 10.1146/annurev-med-062913-051343.
[12] Freeman SD, Virgo P, Couzens S, et al.Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia[J]. J Clin Oncol, 2013, 31(32): 4123-4331. DOI: 10.1200/JCO.2013.49.1753.
[13] Ma H, Cheng L, Hao K, et al.Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1[J]. PLoS One, 2014, 9(1): e85113. DOI: 10.1371/journal.pone.0085113.
[14] Barrett D, Brown Ⅵ, Grupp SA, et al.Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies[J]. Paediatr Drugs, 2012, 14(5): 299-316. DOI: 10.2165/11594740-000000000-00000.
[15] Gao AM, Ke ZP, Shi F, et al.Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway[J]. Chem Biol Interact, 2013, 206(1): 100-108. DOI: 10.1016/j.cbi.2013.08.008.
[16] 王乐, 初雅婧, 程涛, 等. PI3K/AKT/mTOR信号通路抑制剂在白血病治疗中的研究进展[J]. 中华血液学杂志, 2015, 36(10): 888-893. DOI: 10.3760/cma.j.issn.0253-2727.2015.10.021.
[17] He Y, Sun L, Xu Y, et al.Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia[J]. Cancer lett, 2018, 420: 49-59. DOI: 10.1016/j.canlet.2018.01.071.
[18] Furman RR, Sharman JP, Coutre SE, et al.Idelalisib and rituximab in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2014, 370(11): 997-1007. DOI: 10.1056/NEJMoa1315226.
[19] Lampson BL, Kim HT, Davids MS, et al.Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia[J]. Blood Adv, 2019, 3(7): 1167-1174. DOI: 10.1182/bloodadvances.2018030221.
[20] Ding W, Shanafelt TD, Lesnick CE, et al.Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis[J]. Br J Haematol, 2014, 164(1): 146-150. DOI: 10.1111/bjh.12564.
[21] Martelli AM, Evangelisti C, Chiarini F, et al.The phosphatidylinositol 3-kinase/Akt/m TOR signaling network as a therapeutic target in acute myelogenous leukemia patients[J]. Oncotarget, 2010, 1(2): 89-103. DOI: 10.18632/oncotarget.114.
[22] Lin M.Experimental study of atorvastatin regulation of HL-60 leukemia cell apoptosis through PI3K/AKT/mTOR[J]. Journal of Hainan Medical University, 2016, 4: 9-12
[23] Lindsley CW.The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update[J]. Curr Top Med Chem, 2010, 10(4): 458-477. DOI: 10.2174/156802610790980602.
[24] Matsuzaki S, Pouly JL, Canis M.Effects of U0126 and MK2206 on cell growth and re-growth of endometriotic stromal cells grown on substrates of varying stiffness[J]. Sci Rep, 2017, 7: 42939. DOI: 10.1038/srep42939.
[25] Airiau K, Mahon FX, Josselin M, et al.PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor[J]. Cell death Dis, 2013, 4(10): e827. DOI: 10.1038/cddis.2013.309.
[26] Konopleva MY, Walter RB, Faderl SH, et al.Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia[J]. Clin cancer Res, 2014, 20(8): 2206-2235. DOI: 10.1158/1078-0432.CCR-13-1978.
[27] Piovan E, Yu J, Tosello V, et al.Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia[J]. Cancer Cell, 2013, 24(6): 766-776. DOI:10.1016/j.ccr.2013.10.022.
[28] Serra V, Markman B, scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations[J]. Cancer Res, 2008, 68(19): 8022-8030. DOI: 10.1158/0008-5472.CAN-08-1385.
[29] Chapuis N, Tamburini J, Green AS, et al.Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia[J]. Clin Cancer Res, 2010, 16(22): 5424-5435. DOI: 10.1158/1078-0432.CCR-10-1102.
[30] Yu Z, Xie G, Zhou G, et al.NVP-BEZ235,a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells[J]. Cancer Lett, 2015, 367(1): 58-68. DOI: 10.1016/j.canlet.2015.07.007.
[31] Gazi M, Moharram SA, Marhäll A, et al.The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)[J]. Cancer Lett, 2017, 392: 9-16. DOI: 10.1016/j.canlet.2017.01.035.
[32] 陈文佳, 毛霞, 张彦琼, 等. 青蒿琥酯对肿瘤放化疗增敏作用的研究现状分析和展望[J]. 中国中药杂志, 2019, 44(23): 5231-5239. DOI: 10.19540/j.cnki.cjcmm.20190828.405.
[33] 王朦, 贾国存, 成怡冰, 等. 青蒿素基于PI3K/AKT信号通路对人急性髓系白血病细胞凋亡的作用机制[J]. 实用药物与临床, 2019, 22(10): 1014-1018. DOI: 10.14053/j.cnki.ppcr.201910002.
[34] Tan M, Rong Y, Su Q, et al.Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells[J]. Leuk Res, 2017, 62: 98-103. DOI: 10.1016/j.leukres.2017.09.022.

PI3K/AKT signaling pathway and leukemia

PI3K/AKT信号通路与白血病

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

[1]	Gong Qinying, Chen Shuyan, Zhang Zhenli, Gong Shengzhu. Effect of H2H management model on self-efficacy and mood state of leukemia patients [J]. International Medicine and Health Guidance News, 2021, 27(6): 818-821.
[2]	Gao Lijing, Guo Haoqi, Xu Xianling. Parental stress and its influencing factors in parents of children with acute lymphoblastic leukemia [J]. International Medicine and Health Guidance News, 2021, 27(6): 856-860.